# Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/osimertinib-vs-comparator-egfr-tki-as-first-line-treatment-for-egfrm-advanced/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Sendhilnathan Ramalingam,J.E. Gray,Yuichiro Ohe,Byoung Chul Cho,Johan Vansteenkiste,C. Zhou,Thanyanan Reungwetwattana,Ying Cheng,B. Chewaskulyong,Riyaz Shah,K.H. Lee,P. Cheema,Marcello Tiseo,Thomas John,Meng‐Chih Lin,Fumio Imamura,Rachel Hodge,Yuri Rukazenkov,Jean‐Charles Soria,David Planchard |
| Citations | 68 |
| DOI | 10.1093/annonc/mdz394.076 |
| Fields | Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://doi.org/10.1093/annonc/mdz394.076 |
| OpenAlex ID | https://openalex.org/W2978749769 |
| Type | article |
| Year | 2019 |

## Paper authors

- [C. Zhou](https://scholariq.org/researchers/c-zhou/)

## Paper journal

- [Annals of Oncology](https://scholariq.org/journals/annals-of-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Brain Metastases and Treatment](https://scholariq.org/topics/brain-metastases-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.